全文获取类型
收费全文 | 74430篇 |
免费 | 6935篇 |
国内免费 | 2018篇 |
专业分类
耳鼻咽喉 | 379篇 |
儿科学 | 2363篇 |
妇产科学 | 862篇 |
基础医学 | 8999篇 |
口腔科学 | 1687篇 |
临床医学 | 7482篇 |
内科学 | 14828篇 |
皮肤病学 | 1180篇 |
神经病学 | 4334篇 |
特种医学 | 1487篇 |
外国民族医学 | 9篇 |
外科学 | 7609篇 |
综合类 | 10437篇 |
现状与发展 | 7篇 |
一般理论 | 1篇 |
预防医学 | 5587篇 |
眼科学 | 890篇 |
药学 | 7722篇 |
39篇 | |
中国医学 | 4309篇 |
肿瘤学 | 3172篇 |
出版年
2024年 | 215篇 |
2023年 | 1560篇 |
2022年 | 2195篇 |
2021年 | 3673篇 |
2020年 | 3360篇 |
2019年 | 3064篇 |
2018年 | 2857篇 |
2017年 | 2790篇 |
2016年 | 2919篇 |
2015年 | 2732篇 |
2014年 | 5291篇 |
2013年 | 5895篇 |
2012年 | 4633篇 |
2011年 | 5014篇 |
2010年 | 3813篇 |
2009年 | 3689篇 |
2008年 | 3682篇 |
2007年 | 3394篇 |
2006年 | 3018篇 |
2005年 | 2577篇 |
2004年 | 2154篇 |
2003年 | 1790篇 |
2002年 | 1538篇 |
2001年 | 1405篇 |
2000年 | 1184篇 |
1999年 | 1059篇 |
1998年 | 918篇 |
1997年 | 755篇 |
1996年 | 757篇 |
1995年 | 629篇 |
1994年 | 597篇 |
1993年 | 488篇 |
1992年 | 483篇 |
1991年 | 376篇 |
1990年 | 328篇 |
1989年 | 298篇 |
1988年 | 285篇 |
1987年 | 225篇 |
1986年 | 223篇 |
1985年 | 264篇 |
1984年 | 224篇 |
1983年 | 161篇 |
1982年 | 162篇 |
1981年 | 133篇 |
1980年 | 128篇 |
1979年 | 90篇 |
1978年 | 77篇 |
1977年 | 61篇 |
1976年 | 57篇 |
1974年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
《Surgery for obesity and related diseases》2019,15(7):1219-1224
Endoscopic gastroplasty (EG) has been used in clinical practice to treat obesity. This systematic review has the objective of assessing if there is an acceptable level of scientific evidence on the safety and effectiveness of EG. A thorough search strategy was used up to October 2018, including the 2 most common techniques: endoscopic suturing and the primary obesity surgery endolumenal procedure. The quality of the studies was evaluated through the Joanna Briggs Institute Critical Appraisal tools for use in Systematic Reviews—“Checklist for Case Series”—and summarized using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach. Only 1 randomized controlled trial (moderate GRADE evidence) was found, and the remaining were case reports or small case series (very low GRADE evidence). The literature has low scientific quality. All studies, with 1 exception, are small case series with short follow-up. One of the randomized controlled trials did not meet the primary endpoint for weight loss in both groups (EG × sham) after 1-year follow-up. The case series reported from 16% to 19% total weight loss, but few had more than 6 months of follow-up. Serious adverse events ranged from 2% to 10%. Based on current literature, there is not enough quality scientific evidence regarding long-term weight loss and the procedure’s safety to recommend the use of EG in current clinical practice. 相似文献
22.
【摘要】 报道临床症状不典型的家族性黑棘皮病1家系。先证者女,4岁,自1周岁时,颈部、腹部出现黑色斑片,近年来逐渐扩大至唇周、躯干前部。腹部皮肤全反式共聚焦显微镜检查可见乳头环下延扭曲及沟壑结构,乳头环内可见中高折光颗粒结构。先证者父亲及祖母既往有类似病史,但随着年龄增长色素沉着自发性消退,仅有局部皮纹增粗。采集先证者及父母、祖母外周血,对先证者外周血DNA行Panel靶向测序,结果显示,先证者存在FGFR3基因14号外显子c.1949A>C(p.Lys650Thr)错义突变,Sanger测序验证证实先证者及其父亲和祖母均存在此突变。诊断:家族性黑棘皮病。 相似文献
23.
24.
摘要:目的 基于Hippo信号通路核心基因mRNA表达,探索具有补肾填精壮骨之效的金刚丸治疗去卵巢(ovariectomized,OVX)大鼠骨质疏松症的疗效机制。方法 通过OVX法建立绝经后骨质疏松症(postmenopausal osteoporosis,PMOP)大鼠模型,分正常组、假手术组、模型组、金刚丸高剂量组、金刚丸中剂量组、金刚丸低剂量组、仙灵骨葆对照组、骨化三醇对照组。灌胃12周后,通过X射线骨密度仪检测骨密度、镜下观察股骨头显微形态结构、ELISA法检测血清ALP、实时定量RT-PCR检测骨组织Mst2、Lats1、Taz mRNA表达。结果 ①与正常组比较,模型组股骨骨密度显著降低(P<0.01)、骨微结构显著破坏、血清ALP显著降低(P<0.01)、骨组织Mst2、Lats1 mRNA表达显著升高(P<0.01)、Taz mRNA表达显著降低(P<0.01);②与模型组比较,除金刚丸低剂量组外,各给药组的骨密度均显著升高(P<0.01),各给药组骨微结构破坏均得到改善、血清ALP均显著升高(P<0.01)、骨组织Mst2、Lats1 mRNA表达均显著降低(P<0.01)、Taz mRNA表达均显著升高(P<0.01),均以金刚丸高剂量组最为显著。结论 骨组织Hippo信号通路核心基因Mst2、Lats1 mRNA表达上调,Taz mRNA表达下调可能是PMOP的发病机制之一;金刚丸可能通过下调骨组织Hippo信号通路核心基因Mst2、Lats1 mRNA表达、上调Taz mRNA表达的机制,有效防治PMOP。 相似文献
25.
James Milligan Joseph Lee Matt Smith Lindsay Donaldson Peter Athanasopoulos Kent Bassett-Spiers 《The journal of spinal cord medicine》2020,43(2):223-233
Context: Persons with spinal cord injury (SCI) experience significant challenges when they access primary care and community services.Design: A provincial summit was held to direct research, education, and innovation for primary and community care for SCI.Setting: Toronto, Ontario, Canada.Participants: Key stakeholders (N?=?95) including persons with SCI and caregivers, clinicians from primary care, rehabilitation, and specialized care, researchers, advocacy groups, and policy makers.Methods: A one-day facilitated meeting that included guest speakers, panel discussions and small group discussions was held to generate potential solutions to current issues related to SCI care and to foster collaborative relationships to advance care for SCI. Perspectives on SCI management were shared by primary care, neurosurgery, rehabilitation, and members of the SCI communityOutcome Measures: Discussions were focused on five domains: knowledge translation and dissemination, application of best practices, communication, research, and patient service accessibility.Results: Summit participants identified issues and prioritized solutions to improve primary and community care including the creation of a network of key stakeholders to enable knowledge creation and dissemination; an online repository of SCI resources, integrated health records, and a clinical network for SCI care; development and implementation of strategies to improve care transitions across sectors; implementation of effective care models and improved access to services; and utilization of empowerment frameworks to support self-management.Conclusions: This summit identified priorities for further collaborative efforts to advance SCI primary and community care and will inform the development of a provincial SCI strategy aimed at improving the system of care for SCI. 相似文献
26.
27.
28.
I. R. Reid 《Journal of internal medicine》2015,277(6):690-706
There is an increasing number of effective therapies for fracture prevention in adults at risk of osteoporosis. However, shortcomings in the evidence underpinning our management of osteoporosis still exist. Evidence of antifracture efficacy in the groups of patients who most commonly use calcium and vitamin D supplements is lacking, the safety of calcium supplements is in doubt, and the safety and efficacy of high doses of vitamin D give cause for concern. Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures. However, most trials provide little information regarding long‐term efficacy or safety. A particular concern at present is the possibility that oral bisphosphonates might cause atypical femoral fractures. Observational data suggest that the incidence of this type of fracture increases steeply with duration of bisphosphonate use, resulting in concern that the benefit–risk balance may become negative in the long term, particularly in patients in whom the osteoporotic fracture risk is not high. Therefore, reappraisal of ongoing use of bisphosphonates after about 5 years is endorsed by expert consensus, and ‘drug holidays’ should be considered at this time. Further studies are needed to guide clinical practice in this area. 相似文献
29.
30.
目的观察叶酸和维生素B12对绝经后骨质疏松症妇女的骨代谢及同型半胱氨酸水平的影响。方法 80例绝经后骨质疏松症妇女参加研究。所有参与者随机接受叶酸和维生素B12(n=40)或安慰剂(n=40)治疗。在干预前的基线及干预后3个月和6个月,测量两组患者血清同型半胱氨酸、维生素B12和骨代谢标志物的水平。结果治疗前,两组患者血清同型半胱氨酸、维生素B12和骨代谢标志物水平比较差异无统计学意义(P0.05)。治疗后,两组患者同型半胱氨酸均下降,但比较差异无统计学意义(P0.05)。6个月后各组间血清维生素B12、骨钙素、CTX的变化均有显著改变且差异有统计学意义(P0.05)。结论绝经后骨质疏松症妇女补充叶酸和维生素B12可以一定程度改善同型半胱氨酸及骨代谢指标水平。 相似文献